Kezar Life Sciences Inc
KZR
Get informed when a big investor buys or sells
+ FollowMarket Cap$53.86M
Close$
$9.51
30.4% upside
Current Fair Value
30.4% upsideUndervalued by 30.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $53.86 Million |
|---|---|
| Enterprise Value | $-11,018,667.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.66 |
| Beta | 0.41 |
| Outstanding Shares | 7,343,909 |
Return
| Return on Equity | -69.34% |
|---|---|
| Return on Assets | -66.52% |
| Return on Invested Capital | -63.64% |
Valuation & Multiples
| P/E Ratio | -1.18 |
|---|---|
| PEG | 1.81 |
| Price to Sales | - |
| Price to Book Ratio | 0.91 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.27 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.12 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.98
Average shareholder expectationRevenue Estimate
$500,000
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-1.05
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.7049▲ 70.49% |
|---|---|
| Total Calls | 149,800▲ 26.20% |
| Total Puts | 105,600▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 60.50%▼ 0.41% |
|---|---|
| Total Invested | $32.83M▲ 17.02% |
| Investors Holding | 46▲ 2.00% |
ESG Score
No data
About Kezar Life Sciences Inc
CEO: John Fowler